NCT00414960 is a Phase 2 clinical trial of Enzastaurin in Lung Cancer, sponsored by Eli Lilly and Company.

Who is sponsoring NCT00414960?

NCT00414960 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT00414960?

Interventions in NCT00414960: Enzastaurin, Placebo.

What condition does NCT00414960 study?

NCT00414960 studies Lung Cancer.

Is NCT00414960 still recruiting?

NCT00414960 is currently completed. Last updated 31 August 2020.

Are results published for NCT00414960?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-08-31 · How we verify

NCT00414960

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers

Completed Phase 2 Results posted Last updated 31 August 2020

What this trial tests

Phase 2 trial testing Enzastaurin in Lung Cancer in 40 participants. Completed in 1 September 2010.

Timeline

1 December 2007

Primary endpoint
1 September 2010

1 September 2010

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	40
Start date	1 December 2007
Primary completion	1 September 2010
Estimated completion	1 September 2010
Sites	1 location across United States

Drugs / interventions tested

Enzastaurin — full drug profile →
Placebo

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

45 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in Percentage of Cells Staining Positive for Ki-67 in All Biopsy Specimens at Endpoint
Time frame: Baseline, endpoint (up to 8 months)
The number of cells positively stained for Ki-67 (a marker of cellular proliferation) was enumerated and divided by the total number of cells in each specimen. The average Ki-67 labeling index (LI) (percentage of cells positively labeled with Ki-67) for all histological specimens was then calculated for each participant.

Sponsor's own description

To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.
Gray JE, Altiok S, Alexandrow MG, Walsh FW, et al · · 2013 · cited 6× · PMID 23065656 · DOI 10.1002/cncr.27836

Verify or expand the search:

Other trials of Enzastaurin

Trials testing the same drug.

NCT00709995 — A Study for Participants With Metastatic Renal Cell Carcinoma · Phase 2 · completed

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00414960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 31 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00414960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing